A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Study of Relatlimab and Nivolumab in Patients Under 30 Years Old with Classical Hodgkin Lymphoma (cHL) and Non-Hodgkin Lymphoma (NHL)
Sponsor: Bristol-Myers Squibb Company
Enrolling: Male and Female Patients
IRB Number: AAAU5064
U.S. Govt. ID: NCT05255601
Contact: Nobuko Hijiya, MD: / nh2636@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn more about the safety and effectiveness of relatlimab and nivolumab (also known as the study drugs) in participants with recurrent/relapsed (returned) or refractory (treatment-resistant) classical Hodgkin lymphoma (cHL) and Non-Hodgkin lymphoma (NHL). The rationale for combining relatlimab with nivolumab is because it works in different ways to prevent cancer cells from escaping the immune system. There are 2 main parts to this study. In Part A, different doses of relatlimab and nivolumab will be given together to make sure that the study drug combination is safe and well tolerated in participants with cHL and NHL. In Part B, participants will receive nivolumab and relatlimab at the dose that was chosen from Part A. Part B will look at the effectiveness of the study drug combination in participants with recurrent/relapsed or refractory cHL and NHL. We are only recruiting participants for Part B of the study. Participants will be asked to take cycles nivolumab and relatlimab. The procedures in this study include the general physical examinations, ECG measurements, blood/urine sample collection, tumor scans, follow-up examinations, etc. The participation time frame for the study is 5 years.
This study is closed
Nobuko Hijiya, MD
Do You Qualify?
Are you or your child under the age of 30? Yes No
Have you or your child been diagnosed with Classical Hodgkin Lymphoma (cHL) and Non-Hodgkin Lymphoma (NHL)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nobuko Hijiya, MD